ArticleJournal of thoracic disease2017
Prognostic significance of sites of extrathoracic metastasis in patients with non-small cell lung cancer.
Article in Journal of thoracic disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Development and validation of a prognosis model for patients with brain-metastasis non-small cell lung cancer by machine-learning.Translational cancer research · 2025Article
- Outcomes After Radiation for Oligoprogressive Disease Sites in Patients WithJCO precision oncology · 2025Article
- The dynamic duo: A narrative review on the synergy between stereotactic body radiotherapy and immunotherapy in lung cancer treatment (Review).Oncology reports · 2024Review
- Case Report: Recurrent colonic metastasis from lung cancer-diagnostic pitfalls and therapeutic challenge of a peculiar case.Frontiers in surgery · 2023Article
- High tumor burden in non-small-cell lung cancer: A review of the literature.Journal of clinical and translational research · 2022Review
- Clinical Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients with Liver Metastases: A Network Meta-Analysis of Nine Randomized Controlled Trials.Cancer research and treatment · 2022Article
- Risk factor analysis of bone metastasis in patients with non-small cell lung cancer.American journal of translational research · 2022Article
- Trends in Imaging Patterns of Bronchogenic Carcinoma: Reality or a Statistical Variation? A Single-Center Cross-Sectional Analysis of Outcomes.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2022Article
- Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.Journal of the National Comprehensive Cancer Network : JNCCN · 2021Article
- 4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39Journal for immunotherapy of cancer · 2020Article
- Patterns of Extrathoracic Metastases in Different Histological Types of Lung Cancer.Frontiers in oncology · 2020Article
- Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer.Journal for immunotherapy of cancer · 2019Article
- Patient outcomes post-pulmonary resection for synchronous bone-metastatic non-small cell lung cancer.Journal of thoracic disease · 2019Article
- The homogeneous and heterogeneous risk factors for occurrence and prognosis in lung cancer patients with bone metastasis.Journal of bone oncology · 2019Article
- The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4-ALK Rearranged Non-small Cell Lung Cancer.Frontiers in oncology · 2019Article
- Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancer.Medical oncology (Northwood, London, England) · 2018Article
- [Risk Factors of Non-small Cell Lung Cancer with Bone Metastasis after Therapy].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2018Article
- Multimodality Treatment of Advanced Non-small Cell Lung Cancer: Where are we with the Evidence?Current surgery reports · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetastatic non-small cell lung cancer (NSCLC) continues to have a poor prognosis despite recent advances in both targeted radiotherapy methodologies such as stereotactic body radiotherapy (SBRT) and immunotherapies. The impact of location of metastatic disease in patients with NSCLC has not been investigated; we aimed to investigate this using the Surveillance, Epidemiology, and End Results (SEER) database.
methodsWe included 39,910 patients from the SEER database treated for M1b NSCLC from 2010-2013. We identified patients with metastatic disease in the brain, lung, liver, and bone. We used Kaplan-Meier analyses and Cox proportional hazards models to assess the impact of varying sites of metastatic disease on overall survival (OS).
resultsPatients with disease coded as in the brain without other disease in the lung, liver, or bone had improved OS relative to all other comers with M1b disease (HR =0.84, 95% CI, 0.84-0.90, P<0.001). Likewise, patients with disease coded as in the bone without other disease in the lung, liver, or brain had improved OS relative to all other comers with M1b disease (HR =0.89, 95% CI, 0.86-0.92, P<0.001).
conclusionsThis hypothesis-generating analysis suggests that patients with limited metastatic NSCLC to the bone or brain may particularly benefit from aggressive upfront therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.